GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » LT-Debt-to-Total-Asset

Viela Bio (Viela Bio) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2020)


View and export this data going back to 2019. Start your Free Trial

What is Viela Bio LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Viela Bio's long-term debt to total assests ratio for the quarter that ended in Dec. 2020 was 0.00.

Viela Bio's long-term debt to total assets ratio stayed the same from Dec. 2019 (0.00) to Dec. 2020 (0.00).


Viela Bio LT-Debt-to-Total-Asset Historical Data

The historical data trend for Viela Bio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio LT-Debt-to-Total-Asset Chart

Viela Bio Annual Data
Trend Dec18 Dec19 Dec20
LT-Debt-to-Total-Asset
- - -

Viela Bio Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Viela Bio LT-Debt-to-Total-Asset Calculation

Viela Bio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (A: Dec. 2020 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2020 )/Total Assets (A: Dec. 2020 )
=0/423.257
=0.00

Viela Bio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (Q: Dec. 2020 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2020 )/Total Assets (Q: Dec. 2020 )
=0/423.257
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viela Bio  (NAS:VIE) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Viela Bio LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Viela Bio's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Viela Bio (Viela Bio) Business Description

Traded in Other Exchanges
N/A
Address
One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878
Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Executives
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu director 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd. 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd 10 percent owner SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao director, 10 percent owner SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund 10 percent owner CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao director, officer: Chief Executive Officer 10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz officer: VP, Head of Commercial C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878

Viela Bio (Viela Bio) Headlines

From GuruFocus

Viela Bio Announces Pricing of Public Offering of Common Stock

By Marketwired Marketwired 05-28-2020